Home / 2027 Sector Hub / Best Pharmaceutical Stocks

10 Best Pharmaceutical Stocks to Buy in 2027

Quantitative screening of 175 pharmaceutical companies overlaid with Tradestie's 2027 institutional House Thesis governance

Updated
175 investable peers
2027 Macro Overweight
175
Stocks Analyzed
47.6
Avg. Score
$4.7T
Sector Market Cap
46.0
Top Score
Nov 22, 2026
Last Updated
2027 Macro Overweight Macro Ledger · Nov 21, 2026
2027 Macro & Sector Hub →

Pharmaceutical 2027 Institutional Macro & House Thesis Stance

With 10-year real yields near 2.86% penalizing speculative duration, institutional capital flows are rotating into cash-generative pharmaceutical, medical-device, and diagnostic franchises. Commercial pricing power, aging demographics, and patent-cliff M&A capacity support superior 2027 risk-adjusted returns.

The pharmaceutical sector attracts investor attention amid accelerating innovation in obesity, oncology, and rare diseases, where smaller-cap names with strong clinical pipelines offer asymmetric upside versus large-cap defensives. High Tradestie scores among the top names signal momentum in late-stage assets and potential M&A catalysts.

Top 3 Pharmaceutical Picks

2
LLY
Eli Lilly & Co.
41.4
Tradestie
Score
Dominant metabolic and incretin franchise delivering non-tech secular earnings compounding in a high-real-rate regime.
3
MTSR
Metsera, Inc. Common Stock
82.8
Tradestie
Score
MTSR's leading Tradestie score of 82.8 and $5.5B market cap position it for outsized gains as its metabolic pipeline advances toward potential 2026 commercialization.

2027 Industry Fundamentals

For 2027, sector growth should be supported by expanded GLP-1 and precision-medicine approvals, continued biotech M&A, and lower rates easing financing for clinical development. Pricing reforms and trial setbacks remain key risks for the group.

Complete Stock Rankings

Rank Stock & 2027 House View Score Price Market Cap
1
Regeneron Pharmaceuticals Inc
High-margin immunology and ophthalmology cash flows paired with fortress balance-sheet R&D optionality.
46.0 $920.69 $95.5B
2
Eli Lilly & Co.
Dominant metabolic and incretin franchise delivering non-tech secular earnings compounding in a high-real-rate regime.
41.4 $1347.11 $1.2T
3
Metsera, Inc. Common Stock
82.8 $70.50 $5.5B
4
Kura Oncology, Inc.
72.4 $6.91 $675M
5
Arcutis Biotherapeutics, Inc. Common Stock
72.1 $26.36 $3.4B
6
Rigel Pharmaceuticals Inc. (New)
70.5 $40.09 $776M
7
68.7 $50.78 $7.2B
8
Harmony Biosciences Holdings, Inc. Common Stock
67.1 $32.59 $1.9B
9
Phibro Animal Health Corporation Class A
65.9 $33.29 $1.4B
10
Syndax Pharmaceuticals, Inc.
63.9 $8.72 $822M
11
Avadel Pharmaceuticals plc Ordinary Share
62.9 $21.64 $1.5B
12
CorMedix Inc.
62.7 $5.27 $404M
13
UroGen Pharma Ltd. Ordinary Shares
62.7 $27.65 $1.5B
14
Precigen, Inc. Common Stock
61.8 $4.21 $1.5B
15
Galapagos NV
61.5 $27.73 $2.3B

Top 10 Pharmaceutical Stock Picks: In-Depth Analysis

1

REGN 2027 House Conviction

Regeneron Pharmaceuticals Inc
46.0
Score
$920.69
$95.5B
2027 House Thesis Conviction · Late-Cycle Rotation: Overweight Healthcare, Financials & Energy While Tech Corrects +9.8% vs SPY

High-margin immunology and ophthalmology cash flows paired with fortress balance-sheet R&D optionality.

Company Overview

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and …

Why This Matters

Regeneron Pharmaceuticals Inc is a key player in the Pharmaceutical sector with a Tradestie Score of 46.0.

Profitability Analysis

The company demonstrates strong profitability with margins above industry average, indicating operational efficiency and pricing power.

28.5%
Profit Margin
14.9%
ROE
36.3%
Revenue Growth
20.4
P/E Ratio
Why It's a Buy in 2027

With a score of 46.0, REGN ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

2
41.4
Score
$1347.11
$1.2T
2027 House Thesis Conviction · Late-Cycle Rotation: Overweight Healthcare, Financials & Energy While Tech Corrects +9.8% vs SPY

Dominant metabolic and incretin franchise delivering non-tech secular earnings compounding in a high-real-rate regime.

Company Overview

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Why This Matters

Eli Lilly & Co. is a key player in the Pharmaceutical sector with a Tradestie Score of 41.4.

Profitability Analysis

The company demonstrates strong profitability with margins above industry average, indicating operational efficiency and pricing power.

31.9%
Profit Margin
86.0%
ROE
38.6%
Revenue Growth
44.9
P/E Ratio
Why It's a Buy in 2027

With a score of 41.4, LLY ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

3

MTSR

Metsera, Inc. Common Stock
82.8
Score
$70.50
$5.5B
Company Overview

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations …

Why This Matters

Metsera develops next-generation NuSH analog peptides targeting the obesity and overweight market, a high-growth segment within pharmaceuticals projected to exceed $100 billion annually by 2030.

Profitability Analysis

As a clinical-stage biotech with limited financial data available, Metsera reports no commercial revenue and negative operating margins typical of R&D-focused firms, funded through equity raises and partnerships.

0.0%
Profit Margin
0.0%
Revenue Growth
Why It's a Buy in 2027

The 82.8/100 Tradestie Score signals strong platform differentiation in both injectable and oral formats, positioning Metsera to capture share in the expanding GLP-1 agonist space; positive Phase 2 data readouts expected by 2026 could drive significant valuation upside for early investors.

4

KURA

Kura Oncology, Inc.
72.4
Score
$6.91
$675M
Company Overview

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Why This Matters

Kura Oncology, Inc. is a key player in the Pharmaceutical sector with a Tradestie Score of 72.4.

Profitability Analysis

While margins may be under pressure, strong revenue growth suggests the company is gaining market share and could see margin expansion as it scales.

0.0%
Profit Margin
-224.8%
ROE
10.1%
Revenue Growth
Why It's a Buy in 2027

With a score of 72.4, KURA ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

5

ARQT

Arcutis Biotherapeutics, Inc. Common Stock
72.1
Score
$26.36
$3.4B
Company Overview

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 …

Why This Matters

Arcutis Biotherapeutics, Inc. Common Stock is a key player in the Pharmaceutical sector with a Tradestie Score of 72.1.

Profitability Analysis

While margins may be under pressure, strong revenue growth suggests the company is gaining market share and could see margin expansion as it scales.

5.9%
Profit Margin
14.9%
ROE
45.1%
Revenue Growth
123.5
P/E Ratio
Why It's a Buy in 2027

With a score of 72.1, ARQT ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

6

RIGL

Rigel Pharmaceuticals Inc. (New)
70.5
Score
$40.09
$776M
Company Overview

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral …

Why This Matters

Rigel Pharmaceuticals Inc. (New) is a key player in the Pharmaceutical sector with a Tradestie Score of 70.5.

Profitability Analysis

The company demonstrates strong profitability with margins above industry average, indicating operational efficiency and pricing power.

106.6%
Profit Margin
109.2%
ROE
16.5%
Revenue Growth
2.6
P/E Ratio
Why It's a Buy in 2027

With a score of 70.5, RIGL ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

7

CYTK

Cytokinetics Inc.
68.7
Score
$50.78
$7.2B
Company Overview

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on …

Why This Matters

Cytokinetics Inc. is a key player in the Pharmaceutical sector with a Tradestie Score of 68.7.

Profitability Analysis

While margins may be under pressure, strong revenue growth suggests the company is gaining market share and could see margin expansion as it scales.

0.0%
Profit Margin
-572.1%
ROE
2356.5%
Revenue Growth
Why It's a Buy in 2027

With a score of 68.7, CYTK ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

8

HRMY

Harmony Biosciences Holdings, Inc. Common Stock
67.1
Score
$32.59
$1.9B
Company Overview

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the …

Why This Matters

Harmony Biosciences Holdings, Inc. Common Stock is a key player in the Pharmaceutical sector with a Tradestie Score of 67.1.

Profitability Analysis

The company demonstrates strong profitability with margins above industry average, indicating operational efficiency and pricing power.

18.1%
Profit Margin
18.7%
ROE
12.3%
Revenue Growth
10.9
P/E Ratio
Why It's a Buy in 2027

With a score of 67.1, HRMY ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

9

PAHC

Phibro Animal Health Corporation Class A
65.9
Score
$33.29
$1.4B
Company Overview

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company …

Why This Matters

Phibro Animal Health Corporation Class A is a key player in the Pharmaceutical sector with a Tradestie Score of 65.9.

Profitability Analysis

The company maintains a solid financial position in the competitive Pharmaceutical landscape.

6.7%
Profit Margin
28.2%
ROE
6.3%
Revenue Growth
14.2
P/E Ratio
Why It's a Buy in 2027

With a score of 65.9, PAHC ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

10

SNDX

Syndax Pharmaceuticals, Inc.
63.9
Score
$8.72
$822M
Company Overview

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. …

Why This Matters

Syndax Pharmaceuticals, Inc. is a key player in the Pharmaceutical sector with a Tradestie Score of 63.9.

Profitability Analysis

While margins may be under pressure, strong revenue growth suggests the company is gaining market share and could see margin expansion as it scales.

-72.3%
Profit Margin
-426.4%
ROE
81.6%
Revenue Growth
Why It's a Buy in 2027

With a score of 63.9, SNDX ranks among the top Pharmaceutical stocks for 2027. Investors may find value in its market position and growth potential.

Methodology & House Thesis Governance

Stocks are ranked using the Tradestie Score (0–100), combining fundamental profitability, revenue & earnings growth, valuation discipline, and momentum, overlaid with our 2027 institutional House Thesis governance ledger. Stocks in active House Avoid sleeves are explicitly separated into the Consensus Trap Watchlist rather than promoted as buys. Learn more about our methodology or audit live tripwires on the House Thesis Scoreboard.